



EFFICACY OF THE SILENTAIRE PLASMA 24" AIR STERILIZER AGAINST AEROSOLIZED SARS-COV-2

PROJECT: SILENTAIRE PLASMA 24" AIR STERILIZER - SARS-COV-2

PRODUCT: PLASMA 24" AIR STERILIZER

CAP LIC NO: 8860298

CLIA LIC NO: 05D0955926

STATE ID: CLF 00324630

CHALLENGE ORGANISM:

SARS-COV-2 USA-CA1/2020

STUDY COMPLETION DATE:

05/18/2022

Medical Director

Dana Yee, M.D.

Testing Facility

Innovative Bioanalysis, Inc.

3188 Airway Ave Suite D

Costa Mesa, CA 92626

www.InnovativeBioanalysis.com

Email: info@innovativebioanalysis.com

Laboratory Project Number

1235-24



Table of Contents

EFFICACY OF THE SILENTAIRE PLASMA 24" AIR STERILIZER AGAINST AEROSOLIZED SARS-COV-2.....	1
Efficacy Study Summary:.....	3
Study Report:	4
Study Title:	4
Sponsor:	4
Test Facility:.....	4
Device Testing:	4
Study Dates:	4
Study Objective:	4
Test Method:	4
Test System Strains:.....	5
Study Materials and Equipment:.....	7
Control Protocol:	9
Test Procedures:.....	9
Study Results:.....	11
Conclusion:.....	12
Disclaimer.....	13
Appendix A: Model Number Documentation (ETL Report 220301170GZU-001)	14



Efficacy Study Summary:

Study Title	EFFICACY OF THE SILENTAIRE PLASMA 24" AIR STERILIZER AGAINST AEROSOLIZED SARS-COV-2
Laboratory Project #	1235-24
Guideline:	Modified ISO standards as no international standards exist.
Testing Facility	Innovative Bioanalysis, Inc.
GLP Compliance	All internal SOPs and processes follow GCLP guidelines and recommendations.
Test Substance	SARS-CoV-2 USA-CA1/2020
Description	The SilentAire Plasma 24" Air Sterilizer provided by ETI Solid State Lighting (Zhuhai) Ltd was designed as a ceiling-mounted unit that reduces pathogen concentrations in the air. This study sought to determine the device's efficacy in lowering active aerosolized SARS-CoV-2 in a controlled environment.
Test Conditions	Testing was conducted in a 20'x8'x8' chamber following BSL-3 standards. The temperature during testing ranged between 74-75°F, with a relative humidity of 37-42%. A 8.65×10^6 TCID50/mL of SARS-CoV-2 in suspension media was nebulized into the room with mixing fans before collection. Air sample collections occurred at 0, 30, 60, and 120 minutes of device operation.
Test Results	The test results displayed more rapid reductions in viral concentration than natural viability loss observed in the controls. The SilentAire Plasma 24" Air Sterilizer reduced active SARS-CoV-2 to approximately 2.63×10^6 TCID50/mL after 30 minutes. Increased exposure time resulted in a higher observed reduction in recoverable active SARS-CoV-2, as shown by the 5.21×10^4 TCID50/mL after 60 minutes and 1.20×10^2 TCID50/mL after 120 minutes.
Control Results	Control testing was conducted in duplicate without the device, and samples were taken at the corresponding time points used for the challenge. The results displayed a natural viability loss over time in the chamber and were used as a comparative baseline to calculate viral reduction.
Conclusion	The SilentAire Plasma 24" Air Sterilizer demonstrated an ability to reduce active SARS-CoV-2 in the air, as shown by the 99.39% gross reduction after 60 minutes. After 120 minutes, a 99.998% gross reduction was observed.

INNOVATIVE BIOANALYSIS

creating solutions | getting results

Study Report:

Study Title: EFFICACY OF THE SILENTAIRE PLASMA 24" AIR STERILIZER AGAINST AEROSOLIZED SARS-COV-2

Sponsor: ETi Solid State Lighting, Inc.

Test Facility: Innovative Bioanalysis, Inc. 3188 Airway Ave Suite D, Costa Mesa, CA 92626

Device Testing: Silentaire Plasma 24" Air Sterilizer (model number: 559061###) *
(Note: ### maybe 000-999 or blank for internal purposes.)

Study Dates:

Study Report Date: 05/25/2022

Experimental Start Date: 04/26/2022

Experimental End Date: 04/28/2022

Study Completion Date: 05/18/2022

Study Objective:

ETI Solid State Lighting (Zhuhai) Ltd supplied the SilentAire Plasma 24" Air Sterilizer for testing to determine efficacy against viral pathogens. The study evaluated the effectiveness of the SilentAire Plasma 24" Air Sterilizer in its ability to reduce the viral strain referred to as SARS-CoV-2 USA-CA1/2020 within the air.

Test Method:

Bioaerosol Generation:

Nebulization occurred using a Blaustein Atomizing Module (BLAM), as shown in Figure 1, with a pre-set PSI and computer-controlled liquid delivery system. Before testing, the nebulizer was checked for proper functionality by nebulizing the solution without the test virus present to confirm the average particle size distribution. The nebulizer was filled with 8.65×10^6 TCID50/mL of SARS-CoV-2 in suspension media and nebulized at a flow rate of 1mL/min with untreated local atmospheric air. After nebulization, the nebulizer's remaining viral stock volume was weighed to confirm roughly the same amount was nebulized during each run. Bioaerosol procedures for the controls and viral challenges were performed in the same manner with corresponding time points and collection rates.



Figure 1: BLAM Nebulizer

* Note: The 12" Circular Plasma Ceiling Light tested did not include a model number. The model # listed was provided by ETi Solid State Lighting, Inc. with supporting ETL report documentation as included in Appendix A.

INNOVATIVE BIOANALYSIS

creating solutions | getting results

Bioaerosol Sampling:

This study used four probes for air sampling, each connected to a calibrated Gilian 10i vacuum device and set at a standard flow of 5.02L/min with a 0.20% tolerance. Sample collection volumes were set to 10-minute draws per time point, which allowed for approximately 50 liters of air collection per collection port. The air sampler operated with a removable sealed cassette and was manually removed after each sampling time point. Cassettes had a delicate internal filtration disc (Fig. 2) to collect virus samples, which was moistened with a virus suspension media to aid in the collection. Filtration discs from Zefon International, Lot# 28875, were used for testing. At each time point, all the sample discs were pooled into one collection tube to provide an average across the four sampling locations.



Figure 2: Sensidyne 37mm directionnel air flow sample cassette.

Test System Strains: SARS-CoV-2 USA-CA1/2020

The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-CA1/2020, NR-52382.



TCID50 Procedure:

Materials and Equipment:

- Certified Biological Safety Cabinet
- Micropipette and sterile disposable aerosol resistant tips—20uL, 200uL, 1000uL
- Inverted Microscope
- Tubes for dilution
- Hemocytometer with coverslip
- Cell media for infection
- Growth media appropriate for the cell line
- 0.4% Trypan Blue Solution
- Lint-free wipes saturated with 70% isopropyl alcohol
- CO₂ Incubator set at 37°C or 34°C, or other temperature as indicated

Procedure:

1. One day before infection, prepare 96 well dishes by seeding each well with Vero E6 cells in DMEM plus fetal bovine serum, 4mM Glutamine, and antibiotics.
2. On the day of infection, make dilutions of virus samples in PBS.
3. Make a series of dilutions at 1:10 of the original virus sample. Fill the first tube with 2.0mL PBS and the subsequent tubes with 1.8mL.
4. Vortex the viral samples, then transfer 20uL of the virus to the first tube, vortex, and discard tip.
5. With a new tip, serial dilute subsequent tips transferring 200uL.

Additions of virus dilutions to cells:

1. Label the lid of a 96-well dish by drawing grid lines to delineate quadruplicates, number each grid to correspond to the virus sample, and label the rows of the plate for the dilution, which will be plated.
2. Include four (4) negative wells on each plate which will not be infected.
3. Remove all but 0.1mL of media from each well by vacuum aspiration.
4. Starting from the most dilute sample, add 0.1mL of virus dilution to each of the quadruplicate wells for that dilution.
5. Infect four wells per dilution, working backward.
6. Allow the virus to absorb into the cells at 37°C for 2 hours.
7. After absorption, remove the virus inoculum. Start with the most dilute and work backward.
8. Add 0.5mL infection medium to each well, being careful not to touch the wells with the pipette.
9. Place plates at 37°C and monitor CPE using the inverted microscope over a period of 1 to 4 weeks.
10. Record the number of positive and negative wells.

INNOVATIVE BIOANALYSIS

creating solutions | getting results

Study Materials and Equipment:

Equipment Overview: The equipment (Fig. 3) arrived at the laboratory pre-packaged by the manufacturer and was inspected for damage upon arrival. Due to the closed design, no assessment was conducted on the inner components of the device. No product label indicating the name, model, or serial number was found on the device. The device was powered on to confirm functionality before testing. Ion generation was confirmed using two Alpha Lab AIC2 ion polarity meters placed inside the room while the system was. The average ion concentration at the ion meter's location was recorded at approximately 400,000 ions/cm³. It should be noted that due to the nature of ions, there would be fluctuations in concentrations around the entire room.

MANUFACTURER: ETI Solid State Lighting (Zhuhai) Ltd

MAKE: SilentAire Plasma 24" Air Sterilizer

SIZE: 24" x 24" x 16.5"

SERIAL #: N/A



Figure 3. SilentAire Plasma 24" Air Sterilizer as tested.

Testing Layout:

Testing was conducted in a sealed 20'x8'x8' chamber per Biosafety Level 3 (BSL3) standards. The room had a displacement volume of 1,280 ft³ (36,245.56 L) of air. The room remained closed to prevent any air from entering and leaving the room during testing. A nebulizing port connected to a programmable compressor system was located in the center of the 20 ft wall protruding 24 inches from the wall opposite the door. At each chamber corner, low-volume mixing fans (approx. 30 cfm each) were positioned at 45-degree angles to ensure homogenous mixing of bioaerosol concentrations when nebulized into the chamber. The room was equipped with four probes for air sampling positioned along the room's centerline and located six feet off the chamber floor. The device was mounted as close to the ceiling as possible in the center of the chamber and ran on high fan speed. The chamber was visually inspected, and pressure tested, and all internal lab systems and equipment were reviewed before testing.

INNOVATIVE BIOANALYSIS

creating solutions | getting results



Figure 4. Silentaire Plasma 24" Air Sterilizer mounted in the center of the chamber for testing.




Figure 5. 3D model of the testing layout for control and experimental trials.



Control Protocol:

Control testing was conducted in duplicate without the device operating in the testing chamber to accurately assess the SilentAire Plasma 24" Air Sterilizer. Control samples were taken in the same manner and at the corresponding time points used for the challenge trial to serve as a comparative baseline to assess the viral reduction when the device was operating.

Test Procedures:

Exposure Conditions:

1. The temperature during all test runs was approximately 74-75°F, with a relative humidity of 37-42%.
2. The device fan speed was set at High for all testing.
3. Testing time points were as follows, with T equal to minutes: T-0, T-30, T-60, and T-120.
4. Two controls and three viral challenges were conducted using the same methodology.

Experimental Procedure:

1. Before the initial control test and following each trial, the testing area was decontaminated and prepped per internal procedures.
2. 10mL of an 8.65×10^6 TCID50/mL SARS-CoV-2 in suspension media was nebulized via a dissemination port into the room.
3. After nebulization (T-0), the SilentAire air sterilizing unit was turned on via remote control.
4. At each predetermined time point, the device was turned off for sample collection.
5. Air sampling collections were set to 10-minute continuous draws at the point of sampling.
6. Sample cassettes were manually removed from the collection system and brought to an adjacent biosafety cabinet for extraction and placement into a viral suspension media.
7. All samples were sealed after collection and provided to lab staff for analysis after study completion.

Post Decontamination:

After each viral challenge test, the UV system inside the testing chamber was activated for 30 minutes. After 30 minutes of UV exposure, the air filtration system underwent a 30-minute air purge. All test equipment was cleaned with a 70% isopropyl alcohol solution at the end of each day. Collection lines were soaked in a bleach bath mixture for 30 minutes and then rinsed repeatedly with DI water. The nebulizer and vacuum collection pumps were decontaminated with hydrogen peroxide mixtures.



Preparation of The Pathogen

Viral Stock: SARS-CoV-2 USA-CA1/2020 (BEI NR-52382)

TEST	SPECIFICATIONS	RESULTS
Identification by Infectivity in Vero 6 Cells	Cell Rounding and Detachment	Cell Rounding and Detachment
Next-Generation Sequencing (NGS) of the complete genome using Illumina® iSeq™ 100 Platform	≥ 98% identity with SARS-CoV 2, isolate USA-CA1/2020 GenBank: MN994467.1	99.9% identity with SARS-CoV 2, isolate USA-CA1/2020 GenBank: MN994467.1
Approx. 940 Nucleotides	≥ 98% identity with SARS-CoV 2, strain FDAARGOS_983 isolate USA-CA1/2020 GenBank: MT246667.1	100% identity with SARS-CoV 2, strain FDAARGOS_983 isolate USA-CA1/2020 GenBank: MT246667.1
Titer by TCID50 in Vero E6 Cells by Cytopathic Effect**	Report Results	2.8 X 10 ⁵ TCID50 per mL in 5 days at 37°C and 5% CO ₂
Sterility (21-Day Incubation)		
Harpos HTYE Broth, aerobic	No Growth	No Growth
Trypticase Soy Broth, aerobic	No Growth	No Growth
Sabourad Broth, aerobic	No Growth	No Growth
Sheep Blood Agar, aerobic	No Growth	No Growth
Sheep Blood Agar, anaerobic	No Growth	No Growth
Thioglycollate Broth, anaerobic	No Growth	No Growth
DMEM with 10% FBS	No Growth	No Growth
Mycoplasma Contamination		
Agar and Broth Culture	None Detected	None Detected
DNA Detection by PCR of extracted test article nucleic acid	None Detected	None Detected


**The viral titer listed in the Certificate of Analysis is representative of the titer provided by BEI Resources. These viruses are grown on VeroE6 cells either in-house or at a partner lab to the concentrations listed within the experiment design.

INNOVATIVE BIOANALYSIS

creating solutions | getting results

Study Results:

The graph below displayed recoverable active SARS-CoV-2 with and without the SilentAire Plasma 24" Air Sterilizer unit operating for over 120 minutes. Under controlled conditions, the controls showed a natural viability loss of aerosolized SARS-CoV-2 within the chamber. Across three trials, the device reduced a starting concentration of 8.65×10^6 TCID50/mL SARS-CoV-2 was reduced to 2.64×10^6 , 3.07×10^6 , and 2.17×10^6 TCID50/mL averaging approximately 2.63×10^6 TCID50/mL after 30 minutes. After 60 minutes, 4.47×10^4 , 1.03×10^5 , and 8.42×10^3 TCID50/mL active SARS-CoV-2 was recovered, approximately 5.21×10^4 TCID50/mL. After 120 minutes of operation, the device achieved a reduction greater than assay quantitation limits, represented by the value 1.20×10^2 TCID50/mL.



*** As it pertains to data represented herein, the value of $1.2E+02$ indicates a titer that is lower than the specified limit of quantitation. The limit of quantitation for this assay is $1.2E+02$.

****As it pertains to data represented herein; the percentage error equates to an average of $\pm 5\%$ of the final concentration.



Conclusion:

The SilentAire Plasma 24" Air Sterilizer demonstrated the ability to reduce active, aerosolized SARS-CoV-2 more rapidly than the natural loss rate observed in the controlled environment after 60 minutes of device operation. The device achieved an average 69.64% gross reduction of active SARS-CoV-2 compared to the 29.55% viability loss in the controls after 30 minutes. More prolonged air exposure to the device was correlated to higher reduction rates, as shown by the 99.39% gross reduction with the device after 60 minutes. At 120 minutes, the control and experimental trials observed low concentrations of recoverable active SARS-CoV-2 with a 99.202% loss in the controls and a 99.998% gross reduction with the device. With further testing at a shorter interval for time points there would be increased knowledge at the overall effectiveness of the system.

When aerosolizing pathogens and collecting said pathogens, some variables cannot be fully accounted for, namely, placement of pathogen, collection volume, collection points, drop rate, surface saturation, viral destruction upon collection, viral destruction on aerosolization, and possibly others. Every effort was made to address these constraints with the design and execution of the trials. And these efforts are reflected in the meaningful recovery of the virus in the control test.

Considering the variables, the SilentAire Plasma 24" Air Sterilizer achieved a measurable reduction at each time point (T-30 and T-60). The results observed were consistent with the manufacturer's claim that the device can decrease concentrations of active pathogens. Overall, the device successfully reduced active SARS-CoV-2 in the air by 99.397% after 60 minutes under controlled conditions.

INNOVATIVE BIOANALYSIS

creating solutions | getting results

DocuSigned by:
Dr. Dana Yee M.D.
52F0012FC10C43F...

7/15/2022

Dana Yee M.D

Date

Clinical Pathologist and Medical Director, Innovative Bioanalysis, Inc.

DocuSigned by:
Sam Kabbani
8B4B282DF4B34A3...

7/15/2022

Sam Kabbani, MS, BS, MT(ASCP), CLS

Date

Chief Scientific Officer, Innovative Bioanalysis, Inc.

DocuSigned by:
Albert Brockman
42751B72F2FF40A...

7/15/2022

Albert Brockman

Date

Chief Biosafety Officer, Innovative Bioanalysis, Inc.

DocuSigned by:
Kevin Noble
5DF2797BAA78421...

7/15/2022

Kevin Noble

Date

Laboratory Director, Innovative Bioanalysis, Inc.

[Disclaimer](#)

The Innovative Bioanalysis, Inc. ("Innovative Bioanalysis") laboratory is not certified or licensed by the United States Environmental Protection Agency and makes no equipment emissions claims pertaining to ozone or byproduct of any NVC International Holdings or ETI Solid State Lighting devices. Innovative Bioanalysis, Inc. makes no claims to the overall efficacy of any SilentAire Plasma 24" Air Sterilizer unit. The experiment results are solely applicable to the device used in the trial. The results are only representative of the experiment design described in this report. Innovative Bioanalysis, Inc. makes no claims as to the reproducibility of the experiment results given the possible variation of experiment results even with an identical test environment, viral strain, collection method, inoculation, nebulization, viral media, cell type, and culture procedure. Innovative Bioanalysis, Inc. makes no claims to third parties and takes no responsibility for any consequences arising out of the use of, or reliance on, the experiment results by third parties.

INNOVATIVE BIoANALYSIS

creating solutions | getting results

Appendix A: Model Number Documentation (ETL Report 220301170GZU-001)

intertek Total Quality. Assured.		Listing Constructional Data Report (CDR)	
1.0 Reference and Address			
Report Number	220301170GZU-001	DRAFT Issued: 8-Jul-2022	For Review and Comment
Standard(s)	Electrostatic Air Cleaners [UL 867:2011 Ed.5+R:16Aug2021]		
	Electrostatic Air Cleaners [CSA C22.2#187:2020 Ed.5]		
Applicant	ETI Solid State Lighting (Zhuhai) Ltd.	Manufacturer 1	ETI Solid State Lighting (Zhuhai) Ltd.
Address	No. 1, Zhongzhu Road South, Science & Technology Innovation Coast, High Tech District, ZHUHAI CTIY Guangdong	Address	No. 1, Zhongzhu Road South, Science & Technology Innovation Coast, High Tech District, ZHUHAI CTIY Guangdong
Country	CHINA	Country	CHINA
Contact	Lixue Luo	Contact	Lixue Luo
Phone	0756-3392829	Phone	0756-3392829
FAX	NA	FAX	NA
Email	luolixue@etissl.com.cn	Email	luolixue@etissl.com.cn

Report No. 220301170GZU-001 ETI Solid State Lighting (Zhuhai) Ltd.	Page 2 of 34	DRAFT Issued: 08-Jul-2022 For Review and Comment
2.0 Product Description		
Product	Air Cleaner	
Brand name	ETI, Commercial Electric, Hampton Bay, SILENTAIRE, NVC, Cleanaire, Cleanaire Pro	
Description	The product covered by this report is air purifier, rated 120-277V, 50/60Hz, intended for commercial use only, provided with supply leads for permanently-connection, and the products are intended to be ceiling mounted.	
Models	559061 followed by zero or three numbers.	
Model Similarity	The model name suffix letters "###", can be "#=0-9" or blank represents for internal use.	
Ratings	120-277V, 50/60Hz, 100W, 0.85A	
Other Ratings	NA	

See Full ETL Report for more air cleaner specific details.